Prescient Therapeutics enters strategic collaboration with largest cancer centre in US
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US...
Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US...
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a...
Prescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its drug PTX-100 in...
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and accelerate its proprietary...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.